Valion Bio Inc (VBIO) - Total Assets
Based on the latest financial reports, Valion Bio Inc (VBIO) holds total assets worth $32.47 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Valion Bio Inc - Total Assets Trend (2010–2025)
This chart illustrates how Valion Bio Inc's total assets have evolved over time, based on quarterly financial data. Also see Valion Bio Inc (VBIO) total market value for the company's overall valuation and market capitalisation.
Valion Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Valion Bio Inc's total assets of $32.47 Million consist of 41.2% current assets and 58.9% non-current assets. Review VBIO total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.0% |
| Accounts Receivable | $1.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.24 Million | 7.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Valion Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Valion Bio Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Valion Bio Inc's current assets represent 41.2% of total assets in 2025, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 40.0% of total assets in 2025, down from 100.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 7.1% of total assets.
Valion Bio Inc Competitors by Total Assets
Key competitors of Valion Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Valion Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.11 | 2.24 | 9.61 |
| Quick Ratio | 0.86 | 1.90 | 9.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $336.00K | $1.02 Million | $288.00K |
Valion Bio Inc - Advanced Valuation Insights
This section examines the relationship between Valion Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.52 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 1026.0% |
| Total Assets | $31.61 Million |
| Market Capitalization | $1.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Valion Bio Inc's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Valion Bio Inc's assets grew by 1026.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Valion Bio Inc (2010–2025)
The table below shows the annual total assets of Valion Bio Inc from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $31.61 Million | +1026.01% |
| 2024-12-31 | $2.81 Million | -45.57% |
| 2023-12-31 | $5.16 Million | -12.22% |
| 2022-12-31 | $5.88 Million | +555.08% |
| 2020-12-31 | $896.83K | -65.07% |
| 2019-12-31 | $2.57 Million | +279.89% |
| 2017-12-31 | $675.79K | -42.49% |
| 2016-12-31 | $1.18 Million | +771.68% |
| 2015-12-31 | $134.80K | -70.84% |
| 2014-12-31 | $462.30K | -67.44% |
| 2013-12-31 | $1.42 Million | +162.96% |
| 2012-12-31 | $540.00K | +5300.00% |
| 2011-12-31 | $10.00K | -99.42% |
| 2010-12-31 | $1.72 Million | -- |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more